Global Musculoskeletal Disorders Therapeutics Market 2016-2020

Global musculoskeletal disorders therapeutics market outlook

The analyst at Technavio predicts that the global musculoskeletal disorders therapeutics market will grow progressively and will post a modest CAGR of approximately 4% by 2020. One of the major factors that will drive market growth is the growing unmet medical needs in the global musculoskeletal disorders market. The unavailability of a cure for psoriatic arthritis will induce researchers to develop drugs that increase bone density, replace lost bone, and rebuild bone strength. Furthermore, to gain a competitive advantage, vendors will have to develop cost-competitive drugs with ease of administration that promotes bone building efficiently. For instance, Pfizer recently launched bazedoxifene and obtained US FDA approval for bazedoxifene as part of the combination drug Duavee in the prevention of postmenopausal osteoporosis. The lack of proper treatments and biologic drugs with severe side-effects will create an opportunity for vendors to develop therapies that have better efficacy and safety profiles.

According to the musculoskeletal disorders therapeutics market forecast, the Americas will dominate the market accounting for approximately 52% of the total market share. Higher uptake of existing biologic drugs to treat the condition, the launch of new biologics, and expanded access to medical care due to healthcare issues are factors that will drive the prospects for market growth. In addition, essential health-care benefits provided by employer-sponsored health insurance plans and increasing vendor investments in innovative and cost-effective drugs will also help the Americas to lead the market during the forecast period.

Competitive landscape and key vendors

There is intense competition in the market and few key vendors lead the market with innovative product launches that counter the side-effects of biologic drugs, partnerships that help the research and developments of new medicines, and merger and acquisitions to introduce cost-effective drugs that have a wider customer reach.

Key vendors in the market are 

• AbbVie
• Johnson & Johnson
• Amgen
• Pfizer
• F. Hoffmann-La Roche
• Eli Lilly

Other prominent vendors in the market are 3SBio, AB Sciences, AbGenomics International, Ablynx, Adheron, Akron Molecules, Alder BioPharmaceuticals, Amgen Astellas BioPharma, Ampio Pharmaceuticals, Antares Medical Services, Astellas, AstraZeneca, Baxter, Biocad, Bioiberica, Boehringer Ingelheim, Bone Therapeutics, Can-Fite BioPharma, Celgene Corporation, Celltrion, Cellular Biomedicine, Cerapedics, ChemoCentryx, Chugai Pharmaceutical, Coherus Biosciences, Daiichi Sankyo, Dong-A ST, Edding Pharm, Eisai, Epirus, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos NV, Gedeon Richter, Gilead Sciences, GlaxoSmithKline, Histogenics, IBSA Institut Biochimique, iCeutica, Iltoo Pharma, Incyte Corporation, Innovative Med Concepts, Iroko Pharmaceuticals, ISTO Technologies, KaloBios Pharmaceuticals, KAN Research Institute, Kang Stem Biotech, Kitov Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, MEDIPOST, Medivir, Merck, Mereo, Mesoblast, MOCHIDA PHARMACEUTICAL, MorphoSys, Morphotek, Mycenax, Neomed Institute, Novartis, Omeros Corporation, OrthoTrophix, Osteologix, OxyPharma, PFEnex, Philogen, PhytoHealth Corporation, Plexxikon, PLx Pharma, Protalex, Proximagen Limited, Radius Health, Regeneron Pharmaceuticals, Samsung Bioepis, Samumed, Sandoz, Sanofi, SantoSolve AS, Steminent Biotherapeutics, Stempeutics Research, Taisho Pharmaceutical, Taiwan Liposome Company, Takeda, Tarsa Therapeutics, Techfields Pharma, Tetec , TheraMAB, TiGenix, TissueGene, Tonix Pharmaceuticals, Translational Biosciences, UCB, Vericel, Vertex Pharmaceuticals, Vitaeris, Winston Laboratories, and Zosano Pharma Corporation.

Segmentation based on the type of disease and analysis of the global musculoskeletal disorders therapeutics market

• Rheumatoid arthritis
• Osteoarthritis
• Osteoporosis
• Psoriatic arthritis
• Ankylosing spondylitis
• Fibromyalgia

During 2015, rheumatoid arthritis dominated the market by accounting for approximately 52% of the total market share. It is a chronic inflammatory autoimmune disease, and the symptoms appear slowly with mild pain around the joints coupled with stiffness and fatigue. This condition is most common in people within the age group of 30 to 60 years.

Segmentation based on the type of molecule and analysis of the global musculoskeletal disorders therapeutics market

• Biologics
• Small molecules

During 2015, the biologics molecule segment dominated the market, accounting for around 82% of the total market share. Biologics have a complex structure that does not allow easy identification or characterization and are mostly thermo-labile and susceptible to microbial contamination.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global musculoskeletal disorders therapeutics market?
• What are the key market trends impacting the global musculoskeletal disorders therapeutics market?
• What are the challenges to market growth?
• Who are the key vendors in the global musculoskeletal disorders therapeutics market?
• What are the market opportunities and threats faced by the vendors in the global musculoskeletal disorders therapeutics market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global musculoskeletal disorders therapeutics market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Anxiety Disorders Market 2015-2019
• Global Biologic Therapeutics Market 2015-2019
• Global Bipolar Disorder Therapeutics Market 2015-2019